Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats

Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats

Agomelatine (AGO) is an antidepressant drug with agonistic activity at melatonin receptor 1 (MT1) and MT2 and with neutral antagonistic activity at serotonin receptor 5-HT2C. Although experimental studies show that melatonin reduces hypertriglyceridemia and hepatic steatosis induced by excessive fru...

Full description

Bibliographic Details
Main Authors: Vanessa Barbosa Veronesi, Mariana Rodrigues Pioli, Dailson Nogueira de Souza, Caio Jordão Teixeira, Gilson Masahiro Murata, Junia Carolina Santos-Silva, Fernanda Ballerini Hecht, Julia Modesto Vicente, Silvana Bordin, Gabriel Forato Anhê
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Agomelatine
Fructose
Lipid metabolism
Hepatic steatosis
Melatonin
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221005898

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221005898

Similar Items